Standard BioTools sells SomaLogic for $363.7 million to Illumina.

Standard BioTools Inc. has completed the sale of its SomaLogic, Sengenics, and Sengenics entities to Illumina Inc. for a net cash proceeds of approximately $363.7 million. The disposed entities comprised the company's SomaScan Business, including its SomaScan assay platform and related products and services. The company retained its mass cytometry and microfluidics businesses, which were not part of the transaction.